Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on Dec 04, 2023 11:24am
215 Views
Post# 35767110

Allergan slow walking this to market.

Allergan slow walking this to market.The fact Sirona hasn't even received a milestone payment yet doesn't bode well for an imminent launch of a product.  They'd have to announce receipt of milestone payment as it would be material and that would indicate a product launch was near.

Hopefully Howie put some requirements into the contract forcing Allergan to move forward and hit some timelines or penalties would be payable but I think he basically bent over and gave them whatever they dictated.  Fingers crossed it's not another Wanbang scenario where they take so long it becomes useless to bother moving forward with anything.

So the milestone should be the trigger for the larger investing herd to jump on the Sirona train - until then Howard hasn't given anyone a compelling reason to invest in SBM unless they are gluttons for punishment.
<< Previous
Bullboard Posts
Next >>